HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Imexon

HCID 68791
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
59643-91-3
Standard SMILES
NC1=NC(=O)N2CC12
InChIKey
BIXBBIPTYBJTRY-UHFFFAOYSA-N
Molecular formula
C4H5N3O
Average molar mass
111.1 g/mol
Monoisotopic mass
111.04326179

Overview

Imexon is currently being studied for the treatment of pancreatic, lung, breast, prostate, melanoma, and multiple myeloma cancers. It belongs to the family of drugs called cyanoaziridine derivatives. Also called Amplimexon. Imexon is a cyanoaziridine derivative. Imexon is a thiol-binding small molecule which induces mitochondrial oxidation, a loss of membrane potential and cytochrome C, leading to apoptosis.

Names & identifiers

Preferred name
Imexon
IUPAC
4-amino-1,3-diazabicyclo[3.1.0]hex-3-en-2-one
English name
Imexon
Molecular formula
C4H5N3O
Molecular weight
111.1

Names & synonyms

BM-06002DTXSID10468954-Imino-1,3-diazabicyclo(3.1.0)hexan-2-oneNSC-313425DTXCID90268954-Imino-1,3-diazabicyclo[3.1.0]hexan-2-oneNSC714597RefChem:7906144-imino-1,3-diazabicyclo(3,1,0)-hexan-2-one261-838-24-Amino-1,3-diazabicyclo(3.1.0)hex-3-en-2-one59643-91-3
Show more names
bm06002Imexon (Amplimexon4-IMINO-1,3-DIAZABICYCLO-[3.1.0]HEXAN-2-ONE4-Amino-1,3-diazabicyclo[3.1.0]hex-3-en-2-one1,3-Diazabicyclo[3.1.0]hex-3-en-2-one, 4-amino-
8F63U28T2VAmplimexonImexonImexonumMLS002702958NSC313425NCGC00181304-01Imexon (USAN/INN)

Database identifiers

CAS
59643-91-3
PubChem CID
68791
DTXSID
DTXSID1046895
ChEMBL
CHEMBL146428

Properties

Computed structural properties

XLogP
-1.4
Topological polar surface area
58.5 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
1
Rotatable bonds
0
Heavy atoms
8
Formal charge
0
Complexity
186

Physicochemical properties

Boiling point
231.6 · 231.6±23.0 °C(Predicted)
Density
2.26 · 2.26±0.1 g/cm3(Predicted)
storage temp.
2 · 2-8°C
solubility
Soluble in DMSO
pka
4.79 · 4.79±0.20(Predicted)
form
Solid
color
White to off-white
NCI Dictionary of Cancer Terms
Amplimexon; imexon
FDA UNII
8 F63U28T2V · 8F63U28T2V
NCI Drug Dictionary
Amplimexon
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
315 · H315-H319
Precautionary statements
264 · P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313
WGK Germany
3 · 3

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Safety data

wgk
3
Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H315-H319
Precautionary statements
P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Chemistry & industry

Pharmacology

Mechanism of Action · 1 item

Imexon enters the cell and binds to glutathione and other sulfhydryl compounds, effectively preventing them from scavenging the toxic free radicals. So, particularly in the rapidly dividing cancer cell, free radical build-up in the presence of imexon leads to changes in mitochondrial membrane potential and ultimately to the mitochondria swelling and bursting. Mitochondrial proteins, in particular cytochrome c, are released into the cytoplasm and this activates caspase-mediated apoptosis resulting in cancer cell death. This sequence of events has been well characterized and published in several papers in leading cancer journals. Imexon is probably the only cancer drug under development at this time which exploits this mechanism of action. Imexon is an inhibitor of ribonucleotide reductase, a key enzyme in DNA synthesis that is also a target for gemcitabine. Imexon is also a cell cycle inhibitor and in the presence of the drug cells accumulate in S phase.

Applications

UsesCancer chemotherapy.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
EC Number
261-838-2
Nikkaji
J10.914B